DDInter1702 DDInter740
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Sorafenib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Sorafenib {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Sorafenib {u} (Compound) downregulates {v} (Gene) RRM2
RRM2 {u} (Gene) is downregulated by {v} (Compound) Flecainide
Sorafenib {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Sorafenib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Sorafenib {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is regulated by {v} (Gene) GARS
GARS {u} (Gene) is upregulated by {v} (Compound) Flecainide
Sorafenib {u} (Compound) upregulates {v} (Gene) AARS
AARS {u} (Gene) regulates {v} (Gene) DNAJA3
DNAJA3 {u} (Gene) is downregulated by {v} (Compound) Flecainide
Sorafenib {u} (Compound) upregulates {v} (Gene) GARS
GARS {u} (Gene) regulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Sorafenib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Sorafenib (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Flecainide (Compound)
Sorafenib (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is downregulated by Flecainide (Compound)
Sorafenib (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Sorafenib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Sorafenib (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is regulated by GARS (Gene) and GARS (Gene) is upregulated by Flecainide (Compound)
Sorafenib (Compound) upregulates AARS (Gene) and AARS (Gene) regulates DNAJA3 (Gene) and DNAJA3 (Gene) is downregulated by Flecainide (Compound)
Sorafenib (Compound) upregulates GARS (Gene) and GARS (Gene) regulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Flecainide (Compound)